NCT05799339View on ClinicalTrials.gov

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

Active, not recruitingOBSERVATIONAL

Enrollment

144

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

HIV InfectionsOpioid UseTrauma, Psychological

Trial Locations (1)

19143

Prevention Point Philadelphia, Philadelphia

Sponsors

Lead Sponsor

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

collaborator

University of Miami

OTHER

collaborator

University of Michigan

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Alexis Roth

OTHER

NCT05799339 - Optimizing CAB-LA as PrEP for Women Who Inject Drugs | Biotech Hunter | Biotech Hunter